| __timestamp | Bausch Health Companies Inc. | Teva Pharmaceutical Industries Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 2254600000 | 9216000000 |
| Thursday, January 1, 2015 | 2645000000 | 8296000000 |
| Friday, January 1, 2016 | 2611000000 | 10044000000 |
| Sunday, January 1, 2017 | 2548000000 | 11560000000 |
| Monday, January 1, 2018 | 2351000000 | 10558000000 |
| Tuesday, January 1, 2019 | 2350000000 | 9351000000 |
| Wednesday, January 1, 2020 | 2249000000 | 8933000000 |
| Friday, January 1, 2021 | 2394000000 | 8284000000 |
| Saturday, January 1, 2022 | 2364000000 | 7952000000 |
| Sunday, January 1, 2023 | 2559000000 | 8200000000 |
| Monday, January 1, 2024 | 8480000000 |
Unleashing the power of data
In the competitive landscape of pharmaceuticals, Teva Pharmaceutical Industries Limited and Bausch Health Companies Inc. have been pivotal players. From 2014 to 2023, these companies have shown contrasting trends in their cost of revenue. Teva's cost of revenue peaked in 2017, reaching nearly 11.6 billion, but has since declined by approximately 30% to 8.2 billion in 2023. In contrast, Bausch Health's cost of revenue has remained relatively stable, fluctuating around the 2.4 billion mark, with a slight increase of about 14% from 2014 to 2023. This divergence highlights Teva's strategic shifts and cost management challenges, while Bausch Health maintains a steady course. As the pharmaceutical industry evolves, these trends offer insights into the operational efficiencies and market strategies of these two giants.
Analyzing Cost of Revenue: AbbVie Inc. and Bausch Health Companies Inc.
Cost of Revenue Trends: Zoetis Inc. vs Teva Pharmaceutical Industries Limited
Analyzing Cost of Revenue: Teva Pharmaceutical Industries Limited and Corcept Therapeutics Incorporated
Cost of Revenue Comparison: Teva Pharmaceutical Industries Limited vs Cytokinetics, Incorporated
Cost Insights: Breaking Down Teva Pharmaceutical Industries Limited and Alkermes plc's Expenses
Cost of Revenue Comparison: Teva Pharmaceutical Industries Limited vs Celldex Therapeutics, Inc.
Cost Insights: Breaking Down Teva Pharmaceutical Industries Limited and MiMedx Group, Inc.'s Expenses
BioMarin Pharmaceutical Inc. vs Bausch Health Companies Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Trends: Amneal Pharmaceuticals, Inc. vs Bausch Health Companies Inc.
Analyzing Cost of Revenue: Perrigo Company plc and Bausch Health Companies Inc.
Cost Insights: Breaking Down Bausch Health Companies Inc. and Vericel Corporation's Expenses
Comparing Cost of Revenue Efficiency: Bausch Health Companies Inc. vs Mesoblast Limited